European Patent Office Upholds Introgen Patent

Law360, New York (November 13, 2003, 12:00 AM EST) -- Introgen Therapeutics Inc. said its patent on p53 therapy was upheld by the European Patent Office after being challenged by Schering-Plough Corp.

Earlier this year, Schering-Plough filed an opposition against the issuance of the European patent directed to "combination therapy with p53 and conventional chemotherapy and/or radiation."

This is the third successful outcome over a period of three years in oppositions involving Schering-Plough, Introgen said in a statement.

The patent, exclusively licensed to Introgen from The Board of Regents of The University of Texas System, covers...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.